Epigenomics AG
EPGNF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -30.1% | -92.2% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 83.2% | 75.3% | 97.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,065.2% | -2,313.8% | -31.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -1,315.8% | -2,479.2% | -39.1% |
| EPS Diluted | -3.96 | -5.23 | -14.78 | -4.33 |
| % Growth | 24.3% | 64.6% | -241.3% | – |
| Operating Cash Flow | – | -$0 | -$0 | -$0 |
| Capital Expenditures | – | -$0 | -$0 | -$0 |
| Free Cash Flow | – | -$0 | -$0 | -$0 |